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Abstract
Childhood onset psychiatric disorders, such as Attention Deficit Hyperactivity Disorder (ADHD),
Autism Spectrum Disorder (ASD), Mood Disorders, Obsessive Compulsive Spectrum Disorders
(OCSD), and Schizophrenia (SZ), affect many school age children leading to a lower quality of
life, including difficulties in school and personal relationships that persists into adulthood.
Currently, the causes of these psychiatric disorders are poorly understood resulting in difficulty
diagnosing affected children, and insufficient treatment options. Family and twin studies implicate
a genetic contribution for ADHD, ASD, Mood Disorders, OCSD, and SZ. Identification of
candidate genes and chromosomal regions associated with a particular disorder provide targets for
directed research, and understanding how these genes influence the disease state will provide
valuable insights for improving the diagnosis and treatment of children with psychiatric disorders.
Animal models are one important approach in the study of human diseases, allowing for the use of
a variety of experimental approaches to dissect the contribution of a specific chromosomal or
genetic abnormality in human disorders. While it is impossible to model an entire psychiatric
disorder in a single animal model, these models can be extremely valuable in dissecting out the
specific role of a gene, pathway, neuron subtype, or brain region in a particular abnormal
behavior. In this review we discuss existing transgenic mouse models for childhood onset
psychiatric disorders. We compare the strength and weakness of various transgenic animal models
proposed for each of the common childhood onset psychiatric disorders, and discuss future
directions for the study of these disorders using cutting-edge genetic tools.
Childhood onset psychiatric disorders including Attention Deficit Hyperactivity Disorder
(ADHD), Autism Spectrum Disorder (ASD), Mood Disorders, Obsessive Compulsive
Spectrum Disorders (OCSD), and Schizophrenia (SZ) affect many school age children.
These children typically have a lower quality of life, including difficulties in school and
personal relationships, and these problems persist into adulthood. Additionally, the treatment
and support of these individuals causes severe financial and social burdens on society.
Currently, the causes of these psychiatric disorders are poorly understood. This lack of
knowledge results in difficulty diagnosing affected children, and insufficient treatment
options.
Family and twin linkage studies implicate a genetic contribution for ADHD, ASD, Mood
Disorders, OCSD, and SZ (Hudziak and Faraone, 2010). In some cases single, rare genetic
mutations lead to childhood onset psychiatric disorders (Hudziak and Faraone, 2010).
Additionally, there is a hypothesis that other cases are multigenic, with many genes
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contributing small effects leading to the overall disease state (Hudziak and Faraone, 2010).
Developmental and environmental factors can also influence the severity of symptoms
observed in affected individuals leading to a “spectrum” of behaviors (Dick et al., 2010).
Identification of candidate genes and chromosomal regions associated with a particular
disorder provide targets for directed research, and understanding how these genes influence
the disease state will provide valuable information for improving the diagnosis and
treatment of children with psychiatric disorders.
Animal models are one method commonly utilized in the study of human diseases.
Specifically, animal models can overcome many of the confounding factors that limit
research in human patients including genetic variability and environmental diversity. Some
benefits of using transgenic mice to model human diseases include genetically homogeneous
populations, greater control over environmental conditions, shorter time between
generations, pharmacological studies, and the opportunity for genetic manipulations. The
generation of transgenic mouse models can therefore allow for a controlled approach in
evaluating the consequences of a specific chromosomal or genetic abnormality observed in
human patients.
There are however limitations to using animal models to study psychiatric disorders. Most
importantly, there are many behaviors of psychiatric disorders that are currently impossible
to evaluate in a mouse model. For example, obsessive thinking in OCD, and hallucinations
in SZ cannot be assessed in mice. Thus, researchers are limited to modeling behaviors of
psychiatric disorders that can be assessed in a mouse including hyperactivity, social
interactions, anxiety, and some types of learning and memory (Crawley, 2007). However, it
is important to note that even behaviors that can be assessed in a mouse are not an exact
replica of human behavior. At best, we can make correlations between the observed mouse
behavior and known human behaviors in these disorders.
It is also impossible to model an entire psychiatric disorder in a single animal model.
Psychiatric disorders are complex disorders, and current technology cannot expect to
encompass the entirety of such a complex disorder within a single model (Laporte et al.,
2008). A more realistic approach is to model a specific behavior, or single genetic mutation
associated with a disorder in an individual model. These models can then be used to dissect
out the specific role of a gene, pathway, neuron subtype, or brain region in a particular
behavior.
Establishing a transgenic mouse as a model of a psychiatric disorder requires face, construct,
and predictive validity. Face validity refers to the resemblance of the mouse model
phenotype to the symptoms of the human disorder. In some cases, rodent behaviors can be
directly correlated to human symptoms. For example, pre-pulse inhibition (PPI), a test of
sensory-motor gating, can be evaluated in both humans and rodents (Geyer, 2008). Other
behaviors in mice are correlative to human behaviors. For example, tests to show anxiety-
like behaviors in a mouse include time spent in the open section of the elevated plus maze
and emergence to light in the light dark emergence test. These particular behaviors are not
observed in humans with anxiety; however the observation of the behavior in the mouse is
sufficient to draw a positive correlation in some cases. Table 1 lists behavior tests commonly
used in characterizing mouse models of psychiatric disorders.
Construct validity refers to similarities in the mouse model to the underlying cause of the
human disorder. Gene association and linkage studies can implicate certain genes which are
then targeted in transgenic mouse models and therefore partially address construct validity.
Finally, predictive validity refers to the expected response in the mouse model to treatments
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as observed in human patients. Establishing predictive validity is helpful for evaluating the
potential of future novel therapies for a particular disorder.
In this review we will discuss transgenic mouse models for childhood onset psychiatric
disorders. We will introduce the currently proposed transgenic animal models for common
childhood onset psychiatric disorders, and discuss future directions for the study of these
disorders using cutting-edge genetic tools. We apologize that due to page limitations, we
were unable to list all relevant references in this review.
I. Attention Deficit Hyperactivity Disorder
ADHD is one of the most prevalent childhood psychiatric disorders affecting an estimated
8–12% of school age kids (Biederman and Faraone, 2005). ADHD was originally described
by Bradley et al. in the 1930s. They observed that treatment with sedatives paradoxally
resulted in increased activity in children with what they called minimal brain damage (now
called ADHD) (Bradley, 1937). Additionally, administration of stimulants to these children
resulted in normalized behavior (Bradley, 1937). Today ADHD is characterized by
hyperactivity, impaired sustained attention, impulsivity, and distractibility (APA, 2000).
Family, twin, and adoption studies confirm genetics play an important role in susceptibility
to ADHD (Sharp et al., 2009). Genome wide linkage analysis studies identified peak regions
on chromosome 3, 4, 5, 6, 7, 9, 10, 11, 15, 16,17, and 20 (Sharp et al., 2009). Genetic studies
of candidate genes within these ADHD linkage regions found association of genes involving
the dopamine, serotonin, glutamatergic and adrenergic systems (Sharp et al., 2009).
Many of the current animal models of ADHD are pharmacological or environmental models,
which will not be discussed in this review (For an extensive review of these models see
(Kostrzewa et al., 2008)). Here we will focus on transgenic mouse models of ADHD.
DAT KO
The dopamine transporter (DAT) facilitates the recycling of extracellular dopamine (DA)
(Giros et al., 1996). DAT is a major target for psychostimulants including cocaine and
amphetamine as found through pharmacological studies (Giros and Caron, 1993, Heikkila et
al., 1975). In addition, genetic studies show polymorphisms in the DAT gene are associated
with increased risk of ADHD (Xu et al., 2009), although there are also studies that fail to
identify an association (Langley et al., 2005).
Generation of DAT null (DAT KO) mice led to overall and specific growth disorders, such
as dwarfism, as well as increased premature death (Bosse et al., 1997). Behavior studies
show DAT KO mice are more active in home cage environments and novel environments as
found in the open field test, and show defects in spatial memory as measured by
performance in the radial arm test (Gainetdinov et al., 1999). Administration of
psychostimulants (methylphenidate, dextroamphetamine, and cocaine) attenuates
hyperactivity in DAT KO mice (Gainetdinov et al., 1999). The ability of psychostimulants
to attenuate hyperactivity in DAT KO mice suggests a possible secondary mechanism of
action for psychostimulants, possibly through their effect on other monoamine transporters
(Hall et al., 2009, Riddle et al., 2007).
Administration of the selective serotonin reuptake inhibitor (SSRI) fluoxetine and the
nonselective 5-HT receptor agonist quipazine blocks hyperactivity in DAT KO mice
(Gainetdinov et al., 1999). The selective 5-HT2A R antagonist M100907 also reduced
hyperactivity in DAT KO mice (Barr et al., 2004). This effect of serotonin on hyperactivity
may be mediated by glutamatergic signaling, as blockade of NMDARs prevented the
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inhibitory effects on locomotor activity in DAT KO mice by psychostimulants and serotonin
drugs (Gainetdinov et al., 2001). In particular, glutamatergic and dopaminergic signaling in
the cortico-striatal pathway appears to be important for effects of hyperactivity in DAT KO
mice (Gainetdinov et al., 2001). There are some cases of adults with ADHD responding
positively to duloxetine, a selective serotoninnorepinephrine reuptake inhibitor (SSNRI)
(Tourjman and Bilodeau, 2009). However, currently few studies have explored the
effectiveness of SSRIs and other antidepressants in ADHD (Verbeeck et al., 2009).
DAT KD
The DAT KO (previously described above) had developmental deficits and high levels of
premature death with only 68% survival at 10 weeks of age in knockout animals (Bosse et
al., 1997). Zhuang et al thought to avoid these development issues by creating a DAT
knockdown (DAT KD) by introducing an additional 4Kb of sequence in the promoter region
resulting in decreased transcription to 10% of the normal DAT levels. This approach
successfully prevented the growth defects and high mortality rates observed in the DAT KO
(Zhuang et al., 2001).
DAT KD mice exhibit hyperactive behaviors like the DAT KO mice that are alleviated by
administration of amphetamines or valproate, treatments for ADHD and mania respectively
(Ralph-Williams et al., 2003, Zhuang et al., 2001). Additionally, DAT KD mice show
increased motivation for food rewards (Pecina et al., 2003). Specifically, DAT KD mice had
higher learning acquisition and greater incentive performance for a sweet reward in a
runway test (Pecina et al., 2003). The increased “wanting” in the DAT KD mouse is likened
to drug seeking in models of addiction in humans. However, the increased focus on
obtaining the sweet reward and how this relates to a possible contradiction of inattention in
ADHD has not been addressed.
Another study looked at instrumental learning in the DAT KD mice (Yin et al., 2006). This
study found DAT KD mice do not have impaired learning abilities. Interestingly though, the
DAT KD mice did show a deficit in selectivity of cue control during Pavlovian training.
DAT KD mice would enter the food magazine before the conditional stimulation (CS) as
frequently as during the CS even though no reward was present in the magazine before the
CS (Yin et al., 2006). WT mice showed clear discrimination by entering significantly more
frequently during the CS than the pre-CS. The authors suggest this lack of discrimination
could also represent higher “wanting” (Yin et al., 2006). How this higher “wanting” and
decreased discrimination behavior might relate to impulsivity in ADHD has yet to be
explored. (See also OCSD)
Coloboma Mice
The coloboma mouse was generated by neutron irradiation (Searle, 1966), which resulted in
a mutation on Chromosome 2 affecting the genes SNAP-25 (synaptosomal-associated
protein 25), PCLB-1 (phospholipase c beta-1), and Jag1 (Jagged 1) (Hess et al., 1994). The
coloboma mouse was characterized as a model of ADHD when increased spontaneous
activity compared to control animals was observed in the open field test (Hess et al., 1992).
Some human genetic studies show an association of SNAP-25 to ADHD (Forero et al.,
2009). However, other studies have failed to associate SNAP-25 and ADHD (Hess et al.,
1995). SNAP-25 mutant mice show deficits in PPI, however their ataxia precludes the
ability to assess hyperactivity and other behaviors characteristic of ADHD (Jeans et al.,
2007). Therefore, the current SNAP-25 mouse model cannot confirm SNAP-25 is the gene
causing the ADHD-like behaviors in the Coloboma mice.
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Coloboma pups exhibit delayed neurodevelopmental milestones, hypersensitivity to touch,
and persistent head bobbing which is not observed in control mice (Heyser et al., 1995).
Unfortunately, these mice also have eye dysmorphia, delayed lens attachment, and
micropthalmia (Theiler and Varnum, 1981). Therefore evaluation of behavioral tests in these
mice must be interpreted cautiously.
Altered DA and norepinephrine (NE) concentration is found in the striatum and the Nucleus
Acumbens (NAc) of coloboma mice, which may be a result of altered presynaptic function
(Jones et al., 2001). Mutations in the SNAP-25 gene may contribute to this phenotype as this
protein is involved in docking synaptic vesicles (Jones et al., 2001). The striatum and NAc
play important roles in regulating motor activity, therefore a phenotype of hyperactivity in
these mice is consistent with altered transmission in these brain regions (Wachtel et al.,
1979). Amphetamine administration normalizes hyperactivity in coloboma mice, which is
consistent with treatment of ADHD patients (Hess et al., 1996). A recent study shows the
effect of amphetamine on hyperactivity is mediated specifically through the dopamine 2
(D2) receptor subtype (Fan et al., 2010). Methylphenidate, another psychostimulant,
however results in dose-dependent increases in locomotor activity (Hess et al., 1996). The
difference in response to these psychostimulants is proposed to be likely due to the
difference in mechanistic action between the two drugs (Hess et al., 1996). Specifically,
psychostimulants are categorized on their sensitivity to pretreatment with reserpine, a drug
that disrupts vesicular release by depleting vesicular stores of catecholamines. Amphetamine
is not inhibited by pretreatment with reserpine, and therefore is thought to increase synaptic
DA independent of vesicular release. Methylphenidate is inhibited by pretreatment with
reserpine, and is therefore sensitive to vesicle depletion. The authors suggest that the
opposing effects of amphetamine and methylphenidate may highlight a presynaptic defect
involving SNAP-25 in coloboma mice, however the exact mechanism underlying this effect
has not been explored (Hess et al., 1996).
Decreasing NE transmission by blocking the α-2C adrenergic receptor, or decreasing NE
levels with systemic administration of DSP-4 (N-(2-chloroethyl)-N-ethyl-2-
bromobenzylamine hydrochloride), also led to decreased hyperactivity in the coloboma mice
(Bruno and Hess, 2006, Jones and Hess, 2003). This evidence further suggests the NE
system plays a role in affecting hyperactivity.
Coloboma mice also exhibit inattention and impulsivity, two additional characteristics of
ADHD. Specifically, coloboma mice have disrupted latent inhibition (LI), and show
impaired performance in the delayed reinforcement paradigm (Bruno et al., 2007). Thus,
coloboma mice demonstrate several characteristics associated with ADHD though physical
defects limit the usefulness of this model.
Other ADHD Models
Some ADHD patients show evidence of subtle reductions in the thickness of the anterior and
posterior corpus callosum, a structure connecting the two hemispheres of the brain and
possibly involved in the control of sustained attention (Baumgardner et al., 1996). The
Acallosal I/LN J mouse model is an inbred mouse line that completely lacks the corpus
callosum. This mouse shows poor impulse control and learning difficulties in the Y-maze
and avoidance test, and hyperactivity in the open field (Magara et al., 2000). Human cases
with altered corpus callosum are associated with disorders that have both physical and
mental characteristics that are unrelated to ADHD (Paul et al., 2007). Therefore, the role of
the corpus callosum in human cases of ADHD might be difficult to assess due to the
comorbidity of these disorders.
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Thyroid hormones are critical for normal brain development, and abnormal thyroid hormone
levels in utero have been linked to ADHD like behaviors (Hauser et al., 1998). Resistance to
thyroid hormone (RTH) is caused by mutations in thyroid receptor β (Thrb), which results in
a failure to down-regulate thyroid stimulating hormone (TSH). 70% of children diagnosed
with RTH syndrome are also diagnosed with ADHD (Siesser et al., 2006). Thus, exploring
the potential role of Thrb involvement in ADHD is an intriguing question. Generation of a
transgenic mouse model that expresses a mutated human Thrb, Thrb knock-in (Thrb KI),
results in hyperactivity in the open field test, impulsivity in the delayed reinforcement test,
and inattentiveness in the reaction-time task selectively in male mice in some test conditions
(Siesser et al., 2006). However, to date it is unclear how these sex differences and
conditional responses may relate to ADHD in humans.
Casein Kinase 1 (CK1) is a conserved family of Ser/Thr kinases important for many cellular
processes including cell signaling, circadian rhythm, and cellular trafficking (Knippschild et
al., 2005). The CK1δ isoform is highly enriched in the brain (Zhou et al., 2010), and CK1
regulates the phosphorylation state of DARPP-32 (dopamine and c-AMP regulated phospho-
protein MW 32 kDa), an important, striatum expressed, protein phosphatase inhibitor which
integrates synaptic inputs from various sources including glutamatergic and dopaminergic
inputs (Svenningsson et al., 2004). Thus, DARPP-32 is an important modulator of the
Cortico-Striato-Thalamic-Cortico (CSTC) loop. Overexpression of CK1δ (CK1δ OE) in the
forebrain led to down-regulation of dopamine receptors, increased hyperactivity in the open
field, and decreased anxiety in the elevated plus maze and the novelty suppressed feeding
paradigm, which measures the latency to initiate eating in a novel environment (Zhou et al.,
2010). This hyperactivity was attenuated by treatment with methlyphenidate, sub-maximal
doses of amphetamine, the dopamine 1 (D1)R agonist SKF81297, and the D2R agonist
quinprole (Zhou et al., 2010). Thus, CK1δ OE is proposed as a potential new model for
ADHD.
II. Autism Spectrum Disorder
ASD is a developmental disorder occurring in as many as 1:150 children, with males four
times more likely to be diagnosed than females (CDC, 2009). Clinical diagnosis criteria for
ASD are aberrant reciprocal social interactions, deficits in communication, and stereotyped
repetitive behavior with restricted interest (APA, 2000). Currently, there are no effective
pharmacological treatments for ASD.
Family and twin studies show that ASD is highly heritable (O'Roak and State, 2008).
Additionally, linkage and association studies have identified several potential susceptibility
loci and multiple candidate genes potentially involved in ASD (Abrahams and Geschwind,
2008). Advances in detection of copy number variations (CNVs), rare deletions,
duplications, and single nucleotide polymorphisms (SNPs) identified cases of ASD with
rare, single locus genetic changes that can either be inherited or de novo (Marshall et al.,
2008). Finally, there is a high incidence of ASD symptoms in individuals with monogenetic
disorders such as Rett Syndrome, Fragile X, Angelman Syndrome, and Downs Syndrome
(Moss and Howlin, 2009). Thus ASD arises from many different genetic sources that are in
some cases further influenced by environmental factors leading to high levels of variability
in the severity of behaviors in affected individuals (Herbert et al., 2006).
There are several mouse models of ASD currently being investigated including
environmental, pharmacological, and inbred strains that will not be covered by the scope of
this review (Benno et al., 2009, Kuwagata et al., 2009, Marin et al., 2008, Patterson, 2009,
Singer et al., 2009). In this review we will focus on transgenic mouse models thought to
have characteristics of ASD.
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Developmental Disorders with Autism-like Features
Several developmental disorders with known monogenetic causes display autistic
characteristics (Reiss, 2009). Therefore, mouse models targeting these disorders may be
useful in discovering brain circuits involved in the expression of autism related behaviors.
While one must be cautious of non-autism related physical and mental handicaps associated
with these disorders, these models are still very useful in the study of autism.
Fragile X—Fragile X is a genetic disorder that predominantly affects males and is caused
by a mutation of the Fmr1 (Fragile X mental retardation 1) gene resulting in the loss of
fragile X mental retardation protein (FMRP) (Oostra, 1996). Characteristics of Fragile X
include mental retardation, facial dysmorphology, macroorchidism, seizures, and autistic-
like behaviors (Garber et al., 2008).
Transgenic mouse models of Fragile X show increased susceptibility to limbic seizures (Qiu
et al., 2009). Additionally, deficits in spatial learning by radial arm maze, deficits in object
recognition, deficits in acquiring lever-press/avoidance, and deficits in learning in the Morris
water maze were observed in FMRP null mice (Brennan et al., 2006, D'Hooge et al., 1997,
Mineur et al., 2002, Ventura et al., 2004). Tests of the effect of loss of FMRP on social
behaviors resulted in conflicting data. Some groups identified deficits in social approach and
social anxiety using the three-chamber social approach test (Mineur et al., 2006, Liu and
Smith, 2009), while others found equal or increased social approach (McNaughton et al.,
2008, Spencer et al., 2005). Currently, it is not clear why there are contradictory results.
Differences in experimental design, controls, and animal age are potential reasons (Brodkin,
2008).
FMRP null mice have increased dendritic spine length and altered spine morphology similar
to changes observed in patients with Fragile X and ASD (Irwin et al., 2000). FMRP is an
mRNA binding protein that associates with polyribosomes, including dendritic polysomes,
and is thought to be involved in translational regulation of specific mRNAs (Brown et al.,
2001). FMRP null mice show deficits in cortical long-term potentiation (LTP), and
enhanced mGluR dependent long-term depression (LTD) (Nosyreva and Huber, 2006,
Zhang et al., 2009). Importantly, FMRP is hypothesized to repress mRNA translation in
response to mGluR5 activation (Bear et al., 2004). In support of this hypothesis, transgenic
mice with 50% reduction of mGuR5 on the FMRP null background corrected many of the
phenotypes observed in the FMRP null mice including basal protein synthesis, sensitivity to
audiogenic seizures, and spine density in cortical pyramidal neurons (Dolen et al., 2007).
Also, the mGluR5 antagonist, MPEP, can rescue PPI in FMRP null mice (de Vrij et al.,
2008). Additionally, inhibition of p21-activated kinase (PAK), a downstream target of
FMRP, also rescues some phenotypes of FMRP null mice. Expression of a dominant
negative PAK (dnPAK) in the forebrain corrected dendritic spine morphology, cortical LTP,
and hyperactivity and anxiety as measured by the open field test in the FMRP null mice
(Hayashi et al., 2007). These studies implicate potential new therapeutic targets in treating
fragile X patients.
Rett Syndrome—Another genetic disorder with autistic-like behaviors is Rett syndrome
(Nomura, 2005). Rett syndrome is characterized by normal development for the first 6–18
months of life followed by regression of social, language, and cognitive function, and the
emergence of stereotyped hand movements, decreased brain growth, and motor impairments
(Glaze, 2004). While some cases do see improvement in behavior and communication in
later stages of Rett syndrome, there is not a complete return to normal behavior (APA,
2000). Rett syndrome is an X-linked disorder like Fragile X, however Rett syndrome
primarily affects females with most males dying either in utero or shortly after birth
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(Hoffbuhr et al., 2001). Most cases of Rett syndrome are caused by a mutation in methyl
CpG binding protein 2 (Mecp2), a protein that binds to methylated DNA resulting in both
gene silencing and activation (Chahrour et al., 2008).
Mecp2 mutant mice exhibit phenotypes similar to behaviors observed in patients with Rett
syndrome (Stearns et al., 2007). Generation of Mecp2 null mouse lines led to onset of
symptoms around 5–6 weeks of age with neurological characteristics similar to Rett
syndrome including motor coordination defects (Guy et al., 2001, Chen et al., 2001a). A
truncated mutation of Mecp2 also led to similar onset of characteristic features of Rett
syndrome (Shahbazian et al., 2002). Studies to investigate social interactions show mice
expressing truncated Mecp2 have reduced social interaction with no effect on social
recognition as assessed by the partition test (Moretti et al., 2005). These mice also show
deficits in long-term social memory using the social recognition test, deficits in nest building
and other home cage behaviors, and impaired learning and memory in the Morris water
maze and contextual fear conditioning test (Moretti et al., 2005, Moretti et al., 2006).
A Mecp2 mutant mouse with postnatal loss of expression or forebrain specific deletion still
exhibits social interaction deficits in the partition test and resident intruder paradigm
suggesting loss of Mecp2 plays a critical role in adult neurons in addition to its role during
development (Gemelli et al., 2006, Chen et al., 2001a). Additionally, studies showing that
replacement of Mecp2 in adult mice can correct defects in Mecp2 null mice including
survival, motor defects, and locomotor defects, suggesting some characteristics of Rett
syndrome are not irreversible developmental defects (Guy et al., 2007, Jugloff et al., 2008,
Luikenhuis et al., 2004). Both Mecp2 null mice, and mice expressing truncated Mecp2 show
decreased numbers of synaptic connections and deficits in synaptic plasticity (Belichenko et
al., 2009, Dani and Nelson, 2009, Moretti et al., 2006). Treatment with the growth factors
brain derived neurotrophic factor (BDNF) and insulin-like growth factor 1 (IGF-1)
ameliorate some of the symptoms of Rett syndrome found in Mecp2 null mice (Chang et al.,
2006, Tropea et al., 2009). BDNF and IGF-1 are both known to affect spine morphology
through pathways involving phosphoinositide-3-kinase (PI3K) (Zheng and Quirion, 2004).
Cerebrolysin (CBL), a drug known to have neuroprotective and neurotrophic activity, can
ameliorate symptoms of neurodegeneration and aging, and can also ameliorate dendritic
simplification in mice expressing truncated Mecp2 (Doppler et al., 2008). These studies
suggest defects in dendritic spine morphology may be a contributing factor in the expression
of Rett Syndrome.
15q11–13 Deletion/Duplication—Angelman Syndrome (AS) is a genomically imprinted
disorder that is linked to the 15q11–13 region, and displays autistic-like behaviors (Veltman
et al., 2005). Imprinted genes show expression from only one inherited copy of a gene,
therefore if there is a mutation or deletion of the gene copy that should be expressed, the
second copy cannot compensate resulting in loss of function. AS results from loss of the
maternal copy of Ube3A (ubiquitin protein ligase E3A), a ubiquitin ligase (Clayton-Smith
and Laan, 2003). Interestingly, decreased Ube3A expression has also been observed in a
small number of cases of ASD and Rett syndrome (Samaco et al., 2005). Mice with a
maternal deficit in Ube3a have enhanced seizure susceptibility, deficits in motor
coordination, and reduced spatial learning in the Morris water maze (Miura et al., 2002).
Recent studies address how Ube3a may be affecting neurological processes including
cognitive impairment. Specifically, these studies show Ube3a plays an important role in
experience-dependent plasticity and synapse development (Greer et al., 2010, Yashiro et al.,
2009).
15q11–13 also contains several GABAA receptor (GABR) subunit genes including the
GABRB3, GABRA5, and GABRG3 genes (DeLorey et al., 2008). GABAergic signaling plays
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an important role in brain development (Manent and Represa, 2007), and altered
GABAergic signaling is found in some patients with ASD (Blatt, 2005). Additionally,
polymorphisms in GABRB3 have been associated with autism by a linkage and association
study (Buxbaum et al., 2002).
Gabrb3 null mice have high rates of neonatal mortality (Homanics et al., 1997). Mice that
survive show enhanced seizure susceptibility, abnormal motor coordination, and impaired
learning and memory in the contextual fear conditioning and passive avoidance test
(DeLorey et al., 1998, Homanics et al., 1997). A later study shows Gabrb3 KO mice have
impaired social interaction in the partition test, and impaired nesting behaviors (DeLorey et
al., 2008). Gabrb3 KO mice are also hyperactive but show stereotyped circling and
decreased exploratory behavior in the open field with a novel object, which is suggested as
being an index of non-selective attention in this model (DeLorey et al., 2008).
Duplication of the 15q11–13 chromosomal region is also associated with ASD. This
duplication is present in up to 5% of ASD cases, and is most commonly maternally derived
although evidence for paternally derived duplications is accumulating (Bolton et al., 2004,
Dykens et al., 2004, Roberts et al., 2002, Schroer et al., 1998). On the basis of conserved
human/mouse linkage, generation of a transgenic mouse carrying a 6.3 Mb duplication of
mouse chromosome 7 mirroring the human chromosome 15q11–13 duplication was
generated by Nakatani et al. Mice carrying a paternally derived 15q11–13 duplication results
in poor social interaction in the three chamber social approach test, behavioral inflexibility
in the Morris water maze and Barnes maze test, and abnormal ultrasonic vocalizations in
both neonatal pups separated from their mother and adult mice in the resident intruder test
(Nakatani et al., 2009). These mice also exhibit anxiety as measured by the elevated plus
maze, and depression as measured by the forced swim test (Nakatani et al., 2009). However,
mice carrying a maternally derived duplication did not show any behavioral differences
when compared to WT mice (Nakatani et al., 2009). Thus, while in humans the 15q11–13
duplication is usually maternally derived, these mice do mimic a chromosomal duplication
found in human ASD patients, and several autistic-like behaviors are present in the
paternally derived mice suggesting this could be a good model for studying mechanisms in
ASD-like behavior.
Other Developmental Disorders with Autism-like Features—Other developmental
disorders with autistic-like phenotypes include tuberous sclerosis (TSC), Smith-Lamli-Ortiz
Syndrome (SLOS), and Downs Syndrome (Moss and Howlin, 2009). A mouse model of
TSC, Tsc1 conditional knockout, has enhanced cortical excitability, abnormal spine density
and morphology, and seizures (Meikle et al., 2007). SLOS is a neurodevelopmental disorder
associated with high rates of autism (Sikora et al., 2006). SLOS is caused by mutations in
DHCR7 (7-dehydrocholesterol reductase), which leads to disruption of cholesterol formation
(Fitzky et al., 1998). Cholesterol levels have been shown to be important for synapse
formation (Renner et al., 2009). One study has reported that cholesterol levels are low in
children with autism suggesting that proteins involved in cholesterol synthesis could be
candidate genes for ASD (Tierney et al., 2006). Dhcr7 null mice die soon after birth. A
complex heterozygous model with a single copy deletion of Dhcr7 on one allele and a
human missense mutation in the other allele, Dhcr7ms/− results in increased ventricular size
(Correa-Cerro et al., 2006).
Overall, these studies show genes that cause various neurodevelopmental disorders may also
be relevant to specific changes in autism. It is important to note that these developmental
disorders also have characteristics not associated with ASD. Therefore results from behavior
studies should be critiqued carefully and should consider potential complications from
phenotypes not associated with ASD. One thing we can learn from these models is neural
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circuits and pathways potentially involved in ASD, which may be beneficial in identifying
other potential targets for the study of autism. While not all developmental disorders with
autistic-like behaviors may prove to be useful in studying ASD, there is a wealth of
information to be gained from these models.
Synaptic and Signaling Genes Implicated in ASD
Altered brain growth is a common characteristic of ASD (Courchesne et al., 2004).
Specifically, abnormal growth in the frontal lobe cerebellum and limbic structures are
observed(Courchesne, 2004). These brain regions are important for development of social
behaviors, communication, and motor coordination which are disrupted in patients with
ASD (Sacco et al., 2007). Many proteins and pathways critical for neuronal growth and
organization have been implicated in ASD including extracellular matrix proteins,
neurotrophic factors, neurotransmitters, and transcription factors.
Alterations in synaptic function have also been proposed as a fundamental mechanism
underlying ASD (Zoghbi, 2003). Additionally, as mentioned previously studies in mouse
models of developmental disorders with ASD-like behaviors (FMRP, Mecp2, and Ube3a)
exhibit synaptic defects. Not surprisingly, many of the candidate genes identified in the new
genetic studies are synaptic proteins (Freitag, 2007). Many of these candidate genes have
been made into transgenic animal models and are discussed below.
Neuroligin and Neurexin—Neuroligins and neurexins are trans-synaptic cell adhesion
molecules involved in the formation and maintenance of excitatory and inhibitory synapses
(Craig and Kang, 2007). Genetic studies have identified variations in the neuroligin genes
NLGN1, NLGN4X, and NLGN3 in a few cases of ASD (Betancur et al., 2009). Genetic
studies involving individuals affected with ASD also identified variations in neurexins
including a 2p16.3 deletion involving NRXN1, rare NRXN1 specific deletions, sequence
variants in NRXN1, and chromosomal abnormalities involving 2p16.3/NRXN1 (Betancur et
al., 2009). However, other studies show individuals with deletions and chromosomal
abnormalities involving NRXN1 in non-affected individuals (Betancur et al., 2009). Overall,
there is evidence to support a role of neuroligins and neurexins in a small number of cases of
ASD, and several transgenic models have been generated to explore the role of these
proteins in ASD.
Two independent groups generated a transgenic mouse model that mimicked a point
mutation in NLGN3 found in human ASD patients, NLGN R451C. Tabuchi et al reported
their mice show impaired social interactions in the three chamber social approach test,
enhanced spatial learning in the Morris water maze, and enhanced inhibitory synaptic
transmission with no effect on excitatory transmission (Tabuchi et al., 2007). The second
group, Chadman et al, did not observe the same ASD-like phenotypes in their R451C line
(Chadman et al., 2008). Specifically, using the same behavioral tests, they observed no
difference in social approach or spatial memory in R451C mice compared to WT mice
(Chadman et al., 2008). It is not clear why there is a discrepancy between the two lines.
Possible reasons include the use of different inbred strains for the genetic background, or
differences in methodology between the two studies.
In addition to point mutation knock-in mice, NLGN null mice for NLGN 1, 2, 3, and 4 have
also been generated. NLGN1 null mice show impaired spatial memory using the Morris
water maze, and increased repetitive stereotyped grooming (Blundell et al., 2010). These
mice also exhibit reduced NMDA/AMPA ratios in cortico-striatal synapses and impaired
hippocampal LTP (Blundell et al., 2010). NLGN3 and NLGN4 null mice both exhibit
deficits in ultrasonic vocalization and social behaviors (Jamain et al., 2008, Radyushkin et
al., 2009). NLGN4 null mice display deficient social approach and social memory in the
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three chamber social approach test (Jamain et al., 2008). Additionally, male NLGN4 null
mice showed decreased ultrasonic vocalization when exposed to a female mouse in estrous
(Jamain et al., 2008). These deficits in ultrasonic vocalization are likened to deficits in
communication found in human ASD cases. NLGN3 null mice also display decreased social
memory in the three chamber social approach test and decreased ultrasonic vocalizations
when exposed to a female mouse in estrous (Radyushkin et al., 2009). However, NLGN3
null mice did not show deficits in social interaction (Radyushkin et al., 2009). Finally,
NLGN3 null mice exhibit olfactory deficits in the buried food finding test which may
account for the lack of social memory. Interestingly, some ASD patients also exhibit
olfactory deficits (Bennetto et al., 2007, Suzuki et al., 2003). These models suggest NLGN
variations could be important in some cases of ASD.
There are three NRXN genes (1–3), and each gene encodes for a long (α) and short (β)
isoforms which differ in their extracellular domains (Betancur et al., 2009). Abnormalities in
α-NRXNs but not β-NRXNs are associated with ASD (Yan et al., 2008). Triple α-neurexin
KO mice were not viable, double α-neurexin KO mice survived approximately one week,
and even single α-neurexin KO mice experienced impaired survival (Missler et al., 2003).
Double α-neurexin KO mice show α-neurexins are not critical for synapse formation but are
important in synapse function (Dudanova et al., 2007). Altered functional coupling of Ca2+
channels to the presynaptic membrane and decreased Ca+2-mediated neurotransmitter
release is observed in brain slices from α-NRXN KO mice (Missler et al., 2003). This
phenotype is rescued specifically by α-NRXN not β-NRXN (Zhang et al., 2005). A study
using the single deletion NRXN1-α KO mice reveals altered excitatory transmission in the
hippocampus (Etherton et al., 2009). Behavioral studies show decreased PPI, impaired nest
building activity, and improved motor learning on the rotorod, which measures the ability of
a mouse to maintain balance on a revolving rod over increasing speeds, but no obvious
social defects (Etherton et al., 2009). Thus, NRXN also shows promise as a model for
studying ASD.
22q13.3/SHANK3—SHANK (SH3 and multiple ankyrin repeat domains) is a family of
scaffold proteins highly enriched in postsynaptic densities (Sheng and Hoogenraad, 2007).
Shanks interact with many synaptic proteins including neuroligins, glutamate receptor
complexes, and the cytoskeleton acting as a master scaffold in the PSD (Gerrow et al.,
2006). Interestingly, over-expression of Shank1 in vitro results in dendritic spine
enlargement (Sala et al., 2001). Additionally, expression of Shank3 is sufficient to induce
dendritic spine formation in aspiny neurons (Roussignol et al., 2005). Alternatively,
knockdown of Shank3 leads to decreased dendritic spine size in hippocampal neurons in
vitro (Roussignol et al., 2005).
The smallest deletion capable of causing 22q13.3 deletion syndrome contains three genes
including the Shank3 gene and is characterized by global developmental delays, delayed or
absent speech, and autistic behaviors (Cusmano-Ozog et al., 2007). Genetic studies of
individuals with 22q13.3 syndrome indicate that Shank3 is the critical gene in this disorder
(Bonaglia et al., 2006). Specifically, individuals with balanced translocations involving
Shank3 or breakpoints within the Shank3 gene display ASD characteristics (Bonaglia et al.,
2006). Additionally, individuals with ringed chromosome 22 typically have deletion of the
long arm and exhibit 22q13.3 deletion syndrome characteristics. However, individuals with
a ringed chromosome 22 with no disruption of Shank3 are phenotypically normal (Jeffries et
al., 2005). Additional genetic studies identified variations within the Shank3 gene including
CNVs and SNPs that are associated with ASD (Sykes et al., 2009).
Currently, there are no published transgenic models of a Shank3 knockout. A Shank1 KO
generated by Hung et al exhibits increased anxiety as assessed in the light dark emergence
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test and the open field, impaired contextual fear memory, and impaired long-term memory
retention using the radial arm test (Hung et al., 2008). Shank1, like Shank3, affects synaptic
strength and dendritic spine maturation (Sala et al., 2001). Thus, a Shank3 mutant mouse
could prove to be an interesting model for the study of ASD.
BDNF—BDNF is a neurotrophic factor important for axon guidance, dendritic growth
during development, synaptic modulation, induction of LTP, and certain forms of learning
and memory (Greenberg et al., 2009). BDNF has been identified as a candidate gene for
ASD susceptibility (Pardo and Eberhart, 2007). Additionally, increased plasma levels of
BDNF have been reported in children diagnosed with ASD (Connolly et al., 2006).
While BDNF-null mice die shortly after birth, BDNF heterozygous (BDNF+/−) mice and
conditional BDNF knockouts are viable and show altered behavioral phenotypes (Chan et
al., 2006, Lyons et al., 1999). Forebrain specific deletion of BDNF resulted in males
showing increased locomotor activity in the open field test, while females show increased
depression-like behaviors as determined by the forced swim test and the sucrose preference
test, a test of anhedonia (Monteggia et al., 2007). Targeted deletion of BDNF in either fetal
or postnatal brains and BDNF+/− mice exhibit hyperactivity, increased aggression in the
resident intruder test, and altered serotonergic signaling (Chan et al., 2006, Daws et al.,
2007, Lyons et al., 1999, Rios et al., 2001, Rios et al., 2006). Treatment of BDNF+/− mice
with fluoxetine, an SSRI, ameliorated the increased aggression (Lyons et al., 1999).
Interestingly, BDNF levels are increased in the brains of 5-HT2C knockout mice (Hill et al.,
2010). Reciprocally, 5-HT clearance and function are deficient in BDNF+/− mice
suggesting an association between BDNF levels and serotonin signaling (Daws et al., 2007,
Lyons et al., 1999). Finally, behavioral deficits found in SERT null mice are exacerbated
when crossed to BDNF +/− mice suggesting the effects of SERT and BDNF may have
cumulative detrimental effects (Murphy et al., 2003, Ren-Patterson et al., 2006, Ren-
Patterson et al., 2005). Thus, BDNF may play a role in ASD and other psychiatric disorders,
including Mood Disorders, by modulating serotonin signaling.
Another transgenic model, CADPS-2 (Ca2+-dependent activator protein for secretion 2),
further implicates altered BDNF function as a potential contributor of ASD characteristics.
CADPS-2 is a member of a family of proteins involved in exocytosis of dense-core vesicles,
and is involved in the activity-dependent release of BDNF (Sadakata et al., 2004). Cadps-2
knockout mice show impaired BDNF release (Sadakata et al., 2007). These mice also
exhibit ASD-like behaviors including decreased social interactions when paired in a novel
cage, maternal neglect, decreased interest in novel environments in the open field test, and
home cage hyperactivity (Sadakata et al., 2007).
Serotonin Signaling—Serotonin (5-HT) signaling is involved in many
neurodevelopmental processes including neurogenesis, cell migration, cell survival,
synaptogenesis, and plasticity (Azmitia, 2001). Hyperserotonemia is one of the most
consistent findings in patients with ASD (Hranilovic et al., 2008). Additionally, genetic
studies in ASD patients identified genes involved in serotonin signaling, though some
studies fail to identify these correlations (Huang and Santangelo, 2008). Finally, treatment
with the SSRI fluoxetine mildly improves social behavior and decreases aggression and
stereotyped behavior in children with autism (West et al., 2009). However, a new report
shows no effect. Citalopram, an SSRI commonly prescribed to children with ASD, was
found to be no more effective than placebo at reducing repetitive behaviors in children with
ASD (King et al., 2009, Myers, 2010).
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Several animals with targeted disruption of the serotonin transporter (5-HTT, SERT,
SLC6A4) were generated to investigate the role of serotonin signaling. Bengel et al
generated a 5-HTT null (5-HTT KO) mouse that resulted in insufficient clearing of 5-HT
(Bengel et al., 1998). These 5-HTT KO mice have altered cortical thickness and cell density
(Altamura et al., 2007). Interestingly, patients with variations in the 5-HTT gene have
slower extracellular 5-HT clearance and show decreased gray matter volumes (Canli et al.,
2005). 5-HTT null mice show greater anxiety in the elevated-plus maze, the light dark
emergence test, and the open field (Carroll et al., 2007, Holmes et al., 2003). These mice
also demonstrate hypoactivity, and decreased vertical activity (Kalueff et al., 2007).
Additionally, these mice are more sensitive to stress than WT controls, and have altered
hypothalamic-pituitary-adrenal (HPA) axis signaling (Jiang et al., 2009).
Veenstra-VanderWeele et al. identified a rare nonsynonymous variation in the serotonin
transporter (Gly56Ala) in pedigrees carrying diagnoses of ASD and OCD. This Gly56Ala
variant resulted in constitutively elevated SERT activity in human patients (Veenstra-
Vanderweele et al., 2009). Generation of a transgenic mouse carrying the Gly56Ala variant
showed normal gross morphology, though to date there has been no behavioral
characterization (Veenstra-Vanderweele et al., 2009). Thus, the potential for this model is
currently unknown.
PTEN—PTEN (Phosphatase and tensin homolog on chromosome ten) is a phosphatase for
Phosphatidilinositol 3,4,5 triphosphate (PI3) that antagonizes signaling through the PI3K
pathway and affects cellular proliferation, differentiation, and migration (Stiles, 2009).
PTEN abnormalities are usually associated with syndromes including Cowden's syndrome (a
disorder characterized by the development of hamartomas) and TSC, and often exhibit
features such as macroencephaly, seizures, and mental retardation (Pilarski and Eng, 2004).
Genetic studies show some ASD patients have variations in the PTEN gene (Buxbaum et al.,
2007). Additionally, many individuals affected with Cowden's syndrome and TSC are also
diagnosed with ASD (Goffin et al., 2001). PTEN variations have also been identified in
some ASD patients with macroencephaly (Butler et al., 2005).
Conditional deletion of PTEN in a select population of mature neurons in the cortex and
hippocampus using neuron-specific enolase (Nse)-cre results in decreased social approach
when paired in a neutral cage or in the three chamber social approach test, increased activity
in the open field, and impaired PPI (Kwon et al., 2006, Ogawa et al., 2007). Additionally,
these mice show progressive macroencephaly. This correlates well with abnormalities
observed in Cowden syndrome and may model the increased head circumference seen in
autistic children (Hazlett et al., 2005). In addition to the macroencephaly and behavioral
abnormalities observed in the Nse-Cre PTEN mice, there are also changes in neuronal
morphology observed including loss of polarity and neuronal hypertrophy (Kwon et al.,
2006, Ogawa et al., 2007). mTORC1 (Mammalian target of rapamycin complex 1) is a
downstream target of PTEN (Stiles, 2009). Interestingly, a recent study shows rapamycin, a
specific inhibitor of mTORC1, can reverse many of the behavioral abnormalities seen in the
Nse-Cre PTEN mice (Zhou et al., 2009). These studies suggest downstream targets of PTEN
may be useful therapeutic targets for treating ASD, particularly in cases associated with
macroencephaly.
Oxytocin/ Vasopressin—Oxytocin (OT) is a hypothalamic neuropeptide with receptors
located in various brain regions associated with anxiety and social behavior including the
olfactory bulb, piriform cortex, amygdala, and lateral septum (Landgraf and Neumann,
2004). In particular, OT release can facilitate decreases in anxiety and stress responses
(Parker et al., 2005). Genetic studies have identified OT as a candidate gene of ASD
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(Gregory et al., 2009). Additionally, treatment with OT inhalation increased social
interactions in individuals with ASD (Andari et al., 2010).
Three different OT null mice were generated to study the role of endogenous OT (Gross et
al., 1998, Nishimori et al., 1996, Young et al., 1996). The line generated by Young and
colleagues showed reduced maternal retrieval and reduced aggression when OT null mice
were paired in a neutral cage (DeVries et al., 1997, Pedersen et al., 2006). Odorant detection
defects were observed in female knockouts from the line generated by Gross and colleagues
(Kavaliers et al., 2003). Social memory as assessed in the resident intruder test was deficient
in male knockout mice from the lines generated by Nishimori and colleagues with no
deficits in normal social interactions (Ferguson et al., 2000, Winslow and Insel, 2002).
Additional studies found deletion of either OT or the OT receptor (OTR KO) decreased
social recognition, social memory, and ultrasonic vocalizations of male pups subjected to
social isolation (Lee et al., 2008, Takayanagi et al., 2005). No difference in social approach
in the OT KO was found using the three chamber social approach test (Crawley et al., 2007).
There were some differences in social recognition between the total OTR and the forebrain
specific OTR knockout (OTRFB/FB) (Lee et al., 2008). A follow-up studyfound male
OTRFB/FB mice can differentiate between inter-strain females but not intra-strain females
(Macbeth et al., 2009). These differences between the total and conditional OTR knockouts
could be due to differences in temporal or spatial expression. Further studies to dissect the
specific role of OT in the various social paradigms will be helpful in determining how OT
affects social behavior.
Arginine Vasopressin (AVP), another hypothalamic neuropeptide, may also be altered in
ASD (Yirmiya et al., 2006). Normal AVP function is implicated in typical male social
behaviors in animals including aggression, scent marking, courtship, and pair-bonding
(Carter et al., 2008). Two of the AVP receptors are expressed in the CNS, V1aR and V1bR.
V1aR is located throughout the brain while V1bR is most highly expressed in the amygdala
(de Vries and Miller, 1998). V1aR knockout mice show profound deficits in social
recognition using ovariectamized females introduced to the home cage, and decreased
anxiety in the elevated plus maze and the light dark emergence test (Bielsky et al., 2004).
Social discrimination is rescued with viral reintroduction of the V1aR specifically in the
lateral septum (Bielsky et al., 2005). V1bR knockout mice show reduced social aggression,
reduced social motivation, and impaired social memory (Caldwell et al., 2008). V1bR KO
mice also exhibit decreased ultrasonic vocalizations in social environments both as pups and
adults (Scattoni et al., 2008).
Overall, OT and AVP are thought to be important for social behavior. Transgenic mouse
models of OT and AVP both exhibit ASD-like behaviors. Thus, models of OT and AVP
show great promise for understanding mechanisms involved in social recognition and
interactions, behaviors that are severely affected in ASD.
Other ASD Models
Reelin (RELN) is an extracellular matrix protein involved in cell guidance, dendrite
formation, and synaptogenesis (Tissir and Goffinet, 2003). Genetic studies show a CGG
trinucleotide repeat in the 5'UTR of the Reln gene is associated with cases of ASD (Zhang et
al., 2002). However, a separate study failed to identify an association (Krebs et al., 2002).
Reeler mice have a spontaneous deletion that resulted in a loss of the majority of the Reln
gene (Goffinet, 1984). Homozygous mice completely lack reelin, have severe structural
alterations in several brain regions including the cortex, cerebellum and hippocampus, have
severe ataxia or altered gait, and deficits in ultrasonic vocalizations have been recorded
selectively in socially isolated male pups (Goffinet, 1984, Ognibene et al., 2007).
Alternatively, heterozygous reeler mice show loss of Purkinje cells in the cerebellum and
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subtle neuro-anatomical abnormalities (Tueting et al., 1999). Studies with heterozygous
reeler mice show decreased PPI, deficits in odor discrimination, decreased anxiety in the
elevated plus maze, and impaired conditioned fear in the active avoidance test (Marrone et
al., 2006, Tueting et al., 1999), though some studies do not support these findings (Podhorna
and Didriksen, 2004, Salinger et al., 2003).
Dishevelled-1(Dvl-1) is a protein involved in the Wingless-Int (WNT) signaling pathway.
WNT signaling is involved in cell migration, cell survival, dendritic morphogenesis, and
synapse formation. WNT2 has been identified as a candidate gene for ASD susceptibility
(Wassink et al., 2001). Targeted disruption of Dvl1 leads to altered home cage behavior,
social interaction deficits including subordinate behavior in social dominance paradigms,
and changes in synapse formation (Long et al., 2004). However, these mice demonstrate
normal ultrasonic vocalization, spatial learning, and hippocampal synaptic plasticity (Long
et al., 2004). (See also Mood Disorders)
Engrailed 2 (EN2) is a transcription factor important in neurodevelopment and is critical in
the formation of specific serotonergic and noradrenergic nuclei in the mid- and hindbrain
(Simon et al., 2004). EN2 is also important for the survival of specific subpopulations of
dopaminergic neurons (Sgado et al., 2006). Genetic studies show SNPs of EN2 are
associated with ASD (Benayed et al., 2005), though some studies fail to confirm this (Zhong
et al., 2003). EN2 knockout and missense mutant mice show a decrease in the number of
purkinje neurons (Baader et al., 1998). Additionally, EN2 knockout mice show social
deficits as juveniles in reduced social play and as adults in decreased aggression when
paired in a neutral environment (Cheh et al., 2006). EN2 knockout mice show reduced
spatial learning in the Morris water maze, and are hyperactive with impaired motor
coordination as observed in the open field test (Cheh et al., 2006). A better understanding of
the genes regulated by EN2 and how these genes may be involved in pathways important for
the development of social behaviors may be useful in the study of ASD.
III. Mood Disorders
Bipolar disorder (BD) is a mood disorder characterized by recurrent episodes of mania (type
1) or hypomania (type 2) and episodes of depression in a single individual (APA, 2000).
Other mood disorders include major depressive disorder (MDD), cyclothymia, and BD not
otherwise specified. The risk of developing BD in a lifetime is approximately 1–4%
(Merikangas et al., 2007). BD is highly heritable with many cases having a clear genetic
basis (Barnett and Smoller, 2009). Twin studies show the concordance in MZ twins is 38.5–
43% while DZ twins is only 4.5–5.6% (Kieseppa et al., 2004). Additionally, linkage and
association studies have identified many chromosomal regions and candidate genes for BD
(For a detailed review of BD genetics see (Barnett and Smoller, 2009))
The development of mouse models of BD with the critical feature of cycling between mania
and depression is currently not established. However, there has been success in generating
unipolar models of mania and depression. The discovery of genes directly linked to BD and
a better understanding of the neurological basis of cycling between mania and depression
will facilitate the development of more effective treatment. Several pharmacological,
nutritional, and environmental models are used in the study of Mood Disorders, for a review
of these models see Kato et al (Kato et al., 2007). Here we will focus on transgenic models
of mood disorders.
Clock Mutant
Altered circadian processes including sleep, activity, and hormonal secretions are common
characteristics found in mood disorder patients (Wood et al., 2009). Disruption of sleep/
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wake cycles can trigger manic phases, while stabilization of sleep/wake cycles is often
essential for mood stabilization (Boivin, 2000). Additionally, depression symptoms are more
prevalent in winter months and regions that receive significantly less daylight (Saeed and
Bruce, 1998). Association studies identified several circadian genes as susceptibility genes
for BD including CLOCK, BMAL1 (aryl hydrocarbon receptor nuclear translocator-like),
PERIOD3, ARNTL (aryl hydrocarbon receptor nuclear translocator-like), DBP (D site of
albumin promoter (albumin D-box) binding protein), and TIMELESS (Mansour et al., 2006).
CLOCK is a transcription factor that forms a complex with BMAL1 and induces the
expression of several genes that are involved in regulating circadian rhythm through a time-
delayed transcription-translation feedback loop (King and Takahashi, 2000). Disruption of
the CLOCK gene in mice led to hyperactivity in the open field, disrupted circadian rhythms
and decreased sleep determined by the running wheel test and monitoring of brain wave
patterns, decreased anxiety in the open field and elevated plus maze, increased reward for
sucrose and cocaine using the reward/aversion test, and reduced depression-like behavior in
the forced swim test and the learned helplessness test (King et al., 1997, McClung et al.,
2005, Naylor et al., 2000, Roybal et al., 2007, Easton et al., 2003). Importantly, clinically
relevant doses of lithium improved the manic-like phenotype in the CLOCK mice
(Gelenberg et al., 1989, Roybal et al., 2007). Additionally, reintroduction of WT CLOCK in
the ventral tegmental area (VTA) returned locomotor activity and anxiety levels to near wild
type control levels (Roybal et al., 2007).
The clock gene D-box binding protein (Dbp) is also a candidate gene for BD (Niculescu et
al., 2000). Dbp null mice show lower locomotor activity in the open field and blunted
response to stimulants compared to control animals as seen by atypical reduction in
stereotypy behavior with administration of methamphetamines (Le-Niculescu et al., 2008).
Interestingly, upon infliction of chronic stress, these mice demonstrate a change in
phenotype. Specifically, sleep deprivation leads to increased activity levels, and exposure to
stress leads to increased alcohol intake (Le-Niculescu et al., 2008).
POLG
Defects in mitochondrial DNA (mtDNA) and calcium homeostasis have been found in
patients with BD (Stork and Renshaw, 2005). Additionally, variations in mtDNA have been
associated with BD (Kato, 2002), though one study did not replicate these findings
(Munakata et al., 2004).
mtDNA polymerase (POLG) mutant mice were generated to study chronic progressive
external ophthalmoplegia (CPEO), a mitochondrial disorder that often has comorbidity with
mood disorders (Kasahara et al., 2006). Transgenic mice with forebrain specific expression
of mutant POLG exhibit several behavioral characteristics of BD including altered circadian
rhythm and reduced overall wheel running activity in the running wheel test (Kasahara et al.,
2006). Additionally, female but not male mice show periodic activity changes in relation to
estrous (Kasahara et al., 2006). Treatment with the tricyclic antidepressant, amitriptyline,
which can causes a manic-switch in BD patients also led to a manic switch-like behavioral
change in the POLG mice (Kasahara et al., 2006). Specifically, administration of
amitriptyline resulted in increased wheel running during the light phase and increased
locomoter activity selectively in POLG mice. Importantly, lithium improves the periodic
activity changes associated with the estrous cycle and circadian rhythm disruptions observed
in these mice, but not the overall wheel running activity. The authors suggest the responses
to tricyclic antidepressants and lithium indicate the POLG mice may be a good model for
studying BD.
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Glucocorticoid Receptor
Clinical studies show a majority of patients with depression have hyperactivity of the
hypothalamic-pituitary-adrenal (HPA) system and elevated plasma cortisol levels (Holsboer,
2000). The glucocorticoid receptor (GR) modulates many neuronal functions including
stress responsiveness and cognitive function (de Kloet et al., 1999). Additionally,
BAG-1(BCL2-associated athanogene), a GR co-chaperone, was found to be a target of
mood stabilizers further implicating this pathway as important in BD (Zhou et al., 2005).
Finally, genetic association studies have found gene variations in GR to be associated with
Major Depression (MD) (van West et al., 2006).
Several animal models with altered GR function have been generated including a point
mutation to prevent GR dimerization (GRdim), a brain specific knockout of GR (GRnescre),
and a GR missense model with reduced GR expression in the brain and some peripheral
tissues (Pepin et al., 1992, Reichardt et al., 1998, Tronche et al., 1999). The GRdim model
did not show any depressive, manic, or anxiety-like differences (Oitzl et al., 2001).
GRnescre mice show deficient acquisition of stress-coping as determined by the forced
swim test, and decreased anxiety in the elevated plus maze and light dark emergence test
(Tronche et al., 1999). Missense GR mice show decreased anxiety in the elevated plus maze,
but increased anxiety in the open field (Montkowski et al., 1995, Strohle et al., 1998). The
difference in anxiety phenotypes is suggested to be related to the stress-inducing
environment of the open field (Strohle et al., 1998).
Generation of a transgenic mouse model with forebrain specific over-expression of GR
(GRov) by Wei et al resulted in an animal model with increased sensitivity to both positive
and negative stimulation. Specifically, these mice exhibit increased depression-like
behaviors in the forced swim test, anxiety-like behaviors in the elevated plus maze, high
sensitivity to anti-depressants, and hypersensitivity to cocaine administration (Wei et al.,
2004).
Ridder et al evaluated a pair of GR mutant mice, one with a 50% reduction in GR expression
(GR+/−), and one with over-expression of GR. Under basal conditions the GR+/- mice show
normal levels of cortisol and normal behaviors (Ridder et al., 2005). Stress inducing
protocols generated higher levels of cortisol as well as depression-like behaviors in the
forced swim test and learned helplessness test in GR+/− mice compared to WT.
Alternatively, the GR over-expression mice show greater resistance to depression-like
behaviors compared to WT controls. The GR over-expression mice however, do not exhibit
an anxiety-like phenotype in the elevated zero maze and the light dark emergence test as
observed in the GRov mice that specifically over-express GR in the forebrain (Ridder et al.,
2005, Wei et al., 2004). The authors suggest the use of different promoters in the two lines
could explain the differences in behavioral characteristics between the two lines.
Other Mood Disorder Models
GSK-3β (Glycogen synthase kinase-3β) is a serine/threonine kinase involved in many
different cellular processes (Doble and Woodgett, 2003). One role of GSK-3β is regulation
of circadian rhythm, which as mentioned above is disrupted in BD (Kaladchibachi et al.,
2007). Interestingly, GSK3β activity is inhibited by the WNT signaling cascade through
Dvl1 (a model described in the ASD section) (Chen et al., 2001b). Dvl1 KO mice show
deficits in sensory motor gating, which is impaired in individuals with BD (Lijam et al.,
1997). Importantly, GSK-3β is inhibited by both lithium and valproic acid, which are both
used to treat BD (Chen et al., 1999, Klein and Melton, 1996). However, an association study
failed to identify GSK-3β as a genetic risk factor for BD (Nishiguchi et al., 2006).
Transgenic mice over-expressing GSK-3β have increased locomotor activity and decreased
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habituation, hypophagia, increased acoustic startle response, and increased mobility in the
forced swim test (Prickaerts et al., 2006). Thus it is suggested this could be a model for
hyperactivity as seen in mania.
Wolfram syndrome (WFS) is an autosomal recessive disorder that is defined by the
occurrence of diabetes mellitus and bilateral optic atrophy, and is often accompanied by
depression (Swift et al., 1990). Additionally, the WFS1 gene was mapped to a region on
chromosome 4p16.1, a linkage locus of BD (Polymeropoulos et al., 1994). Interestingly,
variations in the WFS1 gene have been found in patients with BD, MD, SZ, suicide victims,
as well as several other psychiatric disorders without comorbidity of Wolfram syndrome
(Swift and Swift, 2000). Initial characterization of a WFS1 knockout (WFS1 KO) found
these mice show increased endoplasmic reticulum (ER) stress and increased vulnerability to
cell death (Yamada et al., 2006), which is alleviated with administration of valproate, a drug
used in treatment of BD (Kakiuchi et al., 2009). More recent studies with WFS1 KO mice
show normal circadian rhythm in the running wheel test (Kato et al., 2008). However these
mice did show decreased social interaction when paired in a neutral cage, increased
behavioral despair in the active avoidance test and latency to escape the Morris water maze,
and decreased behavioral despair in the forced swim test (Kato et al., 2008, Raud et al.,
2009).
PKCI/HINT1 (Protein Kinase C interacting protein) is a member of the histidine triad (HIT)
protein family (Klein et al., 1998). PKCI was identified as a candidate gene for BD and SZ
through microarray analysis of human postmortem brains diagnosed with BD or SZ
respectively (Elashoff et al., 2007, Vawter et al., 2002). An expression analysis study found
that PKCI expression was primarily found in parvalbumin positive interneurons in the cortex
and limbic regions, which are regions implicated in mood disorders (Liu et al., 2008). PKCI/
HINT1 null mice show normal locomotor activity in the open field, and exhibit greater
sensitivity to amphetamine than WT controls (Barbier et al., 2007). PKCI/HINT1 KO mice
exhibit decreased immobility in the tail suspension test, and this is partially alleviated with
administration of valproate. Additionally, PKCI/HINT1 KO mice exhibit less immobility in
the forced swim test, increased HPA axis basal activity, and increased time spent in the light
compartment during the light dark emergence test, which is consistent with mania-like
behavior (Barbier and Wang, 2009).
IV. Obsessive-Compulsive Spectrum Disorders (OCSD)
Obsessive Compulsive Disorder (OCD) is a disorder characterized by persistent intrusive
thoughts (obsessions) and the expression of ritualistic repetitive behaviors (compulsions)
which are often performed in an attempt to alleviate intense anxiety caused by the obsession
(Leckman et al., 2007). Common obsessions include fear of contamination and fear of
harming oneself or others (Lochner et al., 2008). Common compulsions include excessive
hand washing or grooming, counting, checking, telling or confessing, repeating, and
hoarding (Lochner et al., 2008). OCD affects 1–3% of the world's population, with
approximately equal ratios of affected adult males to females (Rasmussen and Eisen, 1994).
In children, however, there is a 2–3:1 ratio of affected males to females (Kalra and Swedo,
2009). Current treatment of OCD consists of pharmacotherapy, cognitive-behavioral therapy
(CBT), or both. However, treatment at best only partially relieves OCD behaviors. Thus a
better understanding of OCD is necessary to improve the treatment options available.
Other disorders classified as OCSDs include Tourette Syndrome (TS), Trichotillomania
(TTM) or compulsive hair pulling, Body Dysmorphia Disorder (BDD), and
Dermatillomania or Compulsive Skin Pulling (CSP) (Phillips, 2002). Additionally,
compulsive hoarding and eating disorders including anorexia are proposed OCSDs (Bellodi
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et al., 2001, Samuels et al., 2007). In considering the relevant disorders, OCSDs may affect
as much as 10% of the general population (Dell'Osso et al., 2007).
Several genetic studies including twin studies, family studies, and association and linkage
studies show that OCD has a strong genetic component (Nicolini et al., 2009). Twin studies
show monozygotic twins have a greater concordance rate for OCD (80–87%) than dizygotic
twins (47–50%) (Carey and Gottesman, 1981). A family study by Pauls et al. showed
individuals with first-degree relatives diagnosed with OCD have a greater incidence of OCD
(7.9–10%) than relatives of control individuals (2.0%) (Pauls et al., 1995). These findings
were confirmed by additional family studies analyzed by other groups (Grabe et al., 2006,
Nestadt et al., 2000). Linkage studies of families with at least two affected family members
identified a strong association with 9p24, 10p15, 11p15, and 14 (Nicolini et al., 2009). Large
scale analysis studies will be important for confirming these linkage sites. In particular, an
ongoing collaborative genetic study by six universities will collect information from
hundreds of families with individuals diagnosed with OCD (Samuels et al., 2006). This
consortium of data and samples will be available to researchers and is sponsored by the
NIMH. To date, over 60 candidate genes for association with OCD have been identified.
These genes implicate the involvement of the serotonergic, glutamatergic, and dopaminergic
systems in OCD (Nicolini et al., 2009). One particular circuit gaining support as a major
factor in OCD is the cortico-striatal-thalamo-cortical (CSTC) circuit (Ting and Feng, 2008).
D1CT transgenic mouse
The D1CT transgenic mouse model was generated by expressing an intracellular form of
cholera toxin (CT), a neuro-potentiating enzyme, under the control of the D1 promoter
(Campbell et al., 1999). These transgenic mice have chronic potentiation of D1 positive
subsets of neurons in the brain. Expression in the D1CT-7 line was predominantly restricted
to neurons within the intercalated nucleus of the amygdala and cortical area that project to
the striatum and orbitofrontal cortex.
Behavioral studies in D1CT mice show several abnormalities resembling OCD-like
behaviors. Specifically, these mice demonstrated repetitive non-aggressive biting of siblings
during grooming, repetitive climbing/leaping, and extended bouts of repetition during
normal behavior (Campbell et al., 1999). D1CT-7 mice also exhibit increased levels of
anxiety as observed in open field and light dark emergence tests when compared to WT
littermates (McGrath et al., 1999). Additionally, D1CT-7 mice exhibit TS-like behaviors
including juvenile-onset tics defined as isolated head and/or body jerks or shakes
(Nordstrom and Burton, 2002). Importantly, administration of clonidine to D1CT-7 mice
reduced tics observed in these mice similar to results found in human TS patients (Cohen et
al., 1979). Unfortunately, the effect of SSRIs in these mutant mice has yet to be evaluated.
5-HT2C Receptor
The 5-HT2C serotonin receptor (5-HT2C-R) subtype is broadly expressed in the brain and
mediates much of the serotonin signaling in the brain (Goddard et al., 2008). Additionally,
the 5-HT2C-R is thought to mediate the actions of serotonin underlying the therapeutic
benefits of SSRI treatment in OCD (Goddard et al., 2008). The initial characterization of 5-
HT2C-R null mice found that these mice experience mid-life obesity due to hyperphagia, are
prone to death from spontaneous seizures, and exhibit altered sleep homeostasis (Tecott et
al., 1995, Chou-Green et al., 2003b). Later studies observed compulsive behaviors in the 5-
HT2C-R null mice more characteristic of some OCD-like behaviors (Chou-Green et al.,
2003a). Specifically, the 5-HT2C-R null mice show increased chewing of non-nutritive clay
and “neat” chewing patterns in plastic screens suggesting compulsive behavior (Chou-Green
et al., 2003a). This study also observed increased head dipping in knockout mice compared
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to wild type mice (Chou-Green et al., 2003a). The authors suggest the clay and screen
chewing and increased head dipping are comparable to compulsive behaviors observed in
OCD patients. Finally, 5-HT2C-R null mice show less anxiety symptoms than WT mice
(Heisler et al., 2007). These mice show increased time and activity in the open quadrant of
the elevated plus maze, increased time spent in the center of the open field, increased
exploration of novel objects, and increased time in a mirrored chamber (Heisler et al., 2007).
These mice also show decreased corticotropin hormone release from the extended amygdala
in response to anxiety stimuli compared to control mice.
Recently, Kimura et al. generated a transgenic mouse with overexpression of 5-HT2C-R in
the forebrain (C2CR) driven by the CamKIIα promoter (Kimura et al., 2009). These mice
showed elevated anxiety as measured by the elevated plus maze and hypo-locomotion as
measured in the open field. This mouse line does not exhibit weight or eating issues as the
hypothalamus is not affected in this mouse. Thus, 5-HT2C-R mice may be useful in
exploring neuronal circuitry mediating anxiety, which is commonly increased in OCD
patients.
SAPAP3
SAPAP3 (SP90/PSD95-associated protein 3) belongs to a family of four homologous genes
encoding proteins that are widely yet differentially expressed in the nervous system (Welch
et al., 2004). The SAPAP family of proteins are scaffold proteins that localize to excitatory
synapses (Takeuchi et al., 1997). Recent human genetic studies have identified multiple rare
SAPAP3 missense variants in TTM and OCD patients, which suggest an association of
OCD/TTM with SAPAP3 disruption (Zuchner et al., 2009).
Deletion of SAPAP3 (SAPAP3 KO) led to compulsive self-grooming to the point of hair
loss and the development of skin lesions (Welch et al., 2007). Importantly, there was no
evidence for skin abnormalities or sensory innervation defects in these mice suggesting that
the increased grooming is a result of compulsive behavior not skin aggravation.
Additionally, the SAPAP3 KO mice showed increased anxiety in the open field, the light
dark emergence test, and the elevated zero maze (Welch et al., 2007).
SAPAP3 is the only family member that is highly expressed in the striatum (Welch et al.,
2004). Therefore, SAPAP3 KO mice were evaluated for defects in cortico-striatal synaptic
transmission by electrophysiology. Field excitatory postsynaptic currents (fEPSCs) were
decreased in SAPAP3 KO mice (Welch et al., 2007). Importantly, rescue of both the cortico-
striatal dysfunction and compulsive grooming was achieved through viral reintroduction of
WT SAPAP3 specifically into the striatum. These results suggest that synaptic dysfunction
in the striatum might be a central mechanism for the expression of compulsive grooming.
Interestingly, DAT KD mice also show disruption in cortico-striatal synapses, and the D1CT
mice also are suggested to have cortico-striatal defects though it has not been directly tested.
If other models of OCD, specifically models with compulsive/repetitive behaviors, are found
to have similar corticostriatal defects, this could establish a link between a common circuitry
defect with a specific OCD-like behavior.
Administration of 5mg/kg fluoxetine, an SSRI, for six days was able to partially rescue the
compulsive grooming behavior in SAPAP3 KO mice. Fluoxetine treatment also seems to
alleviate anxiety levels as observed through decreased latency in the light dark emergence
test. While a single dose of fluoxetine was not sufficient to alleviate the overgrooming, the
treatment dose and timecourse is lower and shorter than typical treatment with fluoxetine in
OCD patients (Ackerman et al., 1998, Jenike, 2004). Overall, the SAPAP3 KO mouse is a
promising model for understanding the circuitry involved in compulsive/repetitive behavior.
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Slitrk5
Slitrk (SLIT and NTRK-like family, member) proteins (Slitrk1–6) are single-pass
transmembrane proteins that control neurite outgrowth (Aruga and Mikoshiba, 2003).
Variations in Slitrk1 (discussed below) have been identified in patients with TS and TTM
(Abelson et al., 2005, Zuchner et al., 2006). Currently, the potential involvement of other
Slitrk family members in psychiatric disorders is not well characterized. To fully
characterize the expression pattern and evaluate the functional role of Slitrk5, Shmelkov et
al replaced the Slitrk5 gene with a lacZ reporter gene to generate a Slitrk5 knockout (Slitrk5
KO). Expression analysis showed a wide expression pattern including the cortex,
hippocampus, and striatum (Shmelkov et al., 2010).
Behavioral observations of the Slitrk5 KO showed these mice have increased grooming
compared to WT littermates which results in severe skin lesions. Chronic treatment with the
SSRI fluoxetine alleviated the overgrooming behavior in Slitrk5 KO mice but had no effect
on WT mice. Additionally, Slitrk5 KO mice showed increased anxiety-like behaviors as
determined by the elevated plus maze, the open field, and compulsive-like behavior in the
marble burying test (Shmelkov et al., 2010).
Slitrk5 is expressed in many brain regions, however FosB expression, a marker of neuronal
activity, was found to be elevated exclusively in the orbitofrontal cortex of Slitrk5 KO mice
(Shmelkov et al., 2010). Interestingly, imaging studies in patients with OCD also showed
increased activity in the orbitofrontal cortex (Menzies et al., 2008). Slitrk5 KO mice also
had decreased volume and dendritic arbor complexity selectively in the striatum (Shmelkov
et al., 2010). As mentioned previously, defects in cortico-striatal circuitry have been
implicated in OCD, therefore Slitrk5 KO mice were evaluated for defects in cortico-striatal
signaling by electrophysiology. Slitrk5 KO mice had decreased fEPSCs recordings,
indicating these mice have defects in cortico-striatal signaling. Biochemical studies also
showed total and synaptic glutamate receptor subunits were decreased in the striatum.
Overall, the Slitrk5 KO mice exhibit OCD-like behaviors of compulsive grooming and
anxiety, and have selective defects in cortico-striatal signaling. Thus the Slitrk5 KO is a
promising model for the study of cortico-striatal defects in OCD.
Other OCD models
Hoxb8 is a member of the mammalian HOX (homeobox-containing) family of transcription
factors best characterized for their role in early development (Capecchi, 1997). Hoxb8 is
broadly expressed in the adult brain including the basal ganglia, hippocampus, cortex, and
cerebellum (Greer and Capecchi, 2002). To address the role of Hoxb8, Greer and Capecchi
generated a transgenic mouse line that was homozygous for a loss-of-function allele of
Hoxb8. These mice exhibited excessive self and cage mate grooming that resulted in hair
removal and skin lesions both on themselves and wild type cage mates (Greer and Capecchi,
2002). Importantly, these mice were found to have no underlying skin abnormalities and the
lesions developed with 100% penetrance (Greer and Capecchi, 2002). Recently Chen et al.
found that in the brain, Hoxb8 exclusively labels a sub-population of microglia. This sub-
population seems to have a bone marrow origin. They also observed a reduction in the total
number of microglia in Hoxb8 mutant mice compared to WT mice (Chen et al., 2010).
Importantly, their data shows that transplantation of wild-type bone marrow rescues the
excessive grooming in the Hoxb8 mutant mice (Chen et al., 2010). Additionally, deletion of
Hoxb8 selectively in hematopoietic cells using a conditional knockout line was sufficient to
induce pathological grooming in mice (Chen et al., 2010). The authors suggest three
potential mechanisms for the role of microglia in modulating neuronal activity. First, the
release of cytokines could work in parallel with neurotransmitters to stimulate or inhibit
neuronal activity (Chen et al., 2010). Microglia have also been shown to function in
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regulated neuronal cell death during embryogenesis (Frade and Barde, 1998, Marin-Teva et
al., 2004). Therefore, another potential mechanism is through possible loss of appropriate
cell death leading to altered neuronal connectivity resulting in aberrant behavior (Chen et al.,
2010). Finally, microglia processes are very dynamic and have been shown to contact
synapses in an activity dependent manner (Wake et al., 2009). Thus, a third potential
mechanism is through altered microglia modulation of neuronal networks leading to altered
behavior. Importantly, the Hoxb8 subpopulation of microglia are most abundant in the
cortex including the orbital regions, and basal ganglia (Chen et al., 2010). This is intriguing
as the orbitofrontal cortex and basal ganglia are two brain regions implicated in human OCD
(Graybiel and Rauch, 2000, Huey et al., 2008). While these potential mechanisms have yet
to be explored, they propose a very interesting role for the immune system in modulating
behavior.
The DAT KD mouse, previously described above as a model for ADHD and mania, also
exhibits OCD-like behaviors. The hyper-dopaminergic DAT KD mice exhibit sequential
super-stereotypy, and showed greater resistance to disruption of this pattern than control
animals (Berridge et al., 2005). Interestingly, the basal ganglia is thought to organize
sequential patterns of movement and thought, including grooming patterns (Lieberman,
2001, Marsden, 1984). The importance of DAT in regulating dopaminergic
neurotransmission in the basal ganglia suggests that DAT disruption might be directly
associated with OCD.
Aromatase cytochrome P450 (P450arom), the product of the cyp19 gene, catalyzes the final
step of biosynthesis of estrogen from androgens. Estrogen plays an important role in the
development of both males and females. To study the role of aromatase activity in mice,
targeted disruption of the cyp19 gene led to the generation of aromatase knockout (Arko)
mice which are estrogen deficient (Fisher et al., 1998). The absence of estrogen in male
Arko mice, but not female Arko mice, resulted in compulsive behaviors including excessive
grooming, barbering, increased wheel running, and reduced PPI up to 18 months of age (Hill
et al., 2007, van den Buuse et al., 2003). Male Arko mice also exhibit a decrease in the
expression of catechol-O-methyltransferase (COMT), a major enzyme regulating dopamine
degredation, in the hypothalamus with no difference in the frontal cortex (Hill et al., 2007).
Interestingly, low COMT activity has been suggested as a risk factor in human OCD,
specifically in males (Karayiorgou et al., 1999, Pooley et al., 2007, Schindler et al., 2000).
Additionally, some evidence does exist for involvement of the hypothalamus in grooming
and wheel running behaviors (Rhodes et al., 2003). Thus, male Arko mice may be a good
model to evaluate the role of the hypothalamus in OCD-like behaviors.
Expression of Slitrk1, another member of the Slitrk family of proteins, is abundant in the
olfactory bulb, frontal cortex, hippocampus, and amygdala (Katayama et al., 2010).
Variations in Slitrk1 have been identified in patients with TS and TTM (Abelson et al.,
2005, Zuchner et al., 2006). Slitrk1 KO mice show decreased locomotor activity in light
cycles, anxiety-like behaviors in the elevated plus maze and the light dark emergence test,
and depression like behaviors in the forced swim test (Katayama et al., 2010).
Neurochemical analysis of Slitrk1 KO mice show increased NE levels in the mPFC and
NAc, while choline (CH) and acetylcholine (Ach) levels were decreased in the striatum
(Katayama et al., 2010). Both NE and CH/Ach signaling are involved in mediating fear and
anxiety (Brioni et al., 1993, Hu et al., 2007). Interestingly, clonidine, an alpha2-adrenergic
agonist known to be effective in treating some TS patients (Robertson, 2006), was effective
in treating the anxiety in Slitrk1 KO mice but had no effect on locomotor activity (Katayama
et al., 2010).
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V. Schizophrenia
Schizophrenia (SZ) is a neuropsychiatric disorder that affects approximately 1% of the
world's population (Wu et al., 2006). SZ is characterized by the presence of three categories
of symptoms: positive symptoms (hallucinations, delusions, and psychosis), negative
symptoms (anhedonia, social defects, impaired motivation), and cognitive deficits (impaired
working memory, attention, and execution) (APA, 2000). Although onset of SZ typically
occurs in early adulthood (AOS), rare cases of childhood onset SZ (COS) occur in children
as early as six years old (Rapoport et al., 2005). Studies show there is a significant genetic
component for SZ (O'Donovan et al., 2009). Additionally, several pathways have been
implicated in SZ including glutamatergic and GABA-ergic transmission (O'Tuathaigh et al.,
2007).
Many SZ susceptibility genes are also associated with other childhood onset psychiatric
disorders. Therefore many transgenic mouse models of SZ susceptibility genes were
presented in previous sections of this review. For example, PKCI/HINT1 is associated with
both SZ and Mood Disorders. Additionally, reln, BDNF, and neuregulin 1 are associated
with SZ and ASD. Because SZ is mostly an adult onset psychiatric disorder, we have limited
our presentation of SZ models to those genes associated with other disorders discussed in
this review, and in this section the most prominently characterized SZ transgenic models to
date.
22q11 deletion syndrome
22q11 deletion is a chromosomal abnormality associated with mental disorders. The
smallest known deletion affects a minimum of 30 genes, and several of these genes have
been associated with SZ and BD (Lindsay et al., 1995). In fact, patients with the 22q11
deletion exhibit both SZ and BD symptoms (Paylor and Lindsay, 2006). Several models of
22q11 exist including models that mimic the deletion seen in human patients, models with
smaller deletion regions, and models with targeted deletion of specific genes contained
within the deleted region (Jerome and Papaioannou, 2001, Kimber et al., 1999, Lindsay et
al., 1999, Lindsay et al., 2001, Puech et al., 2000, Long et al., 2006).
One model, the Df(16)A+/− transgenic mouse, deletes a subset of genes affected in 22q11
syndrome (Mukai et al., 2008, Stark et al., 2008). Studies involving the Df(16)A+/− mouse
model show impaired PPI, decreased working memory in the T maze, impaired response to
contextual fear-conditioning, hyperactivity in open field, and male mice show higher levels
of anxiety as determined by the light dark emergence test (Stark et al., 2008). Additionally,
lower levels of miRNAs, and synaptic defects in the hippocampus were identified in
Df(16)A+/− mice, which are suggested to contribute to some of the cognitive defects found
in these mice (Mukai et al., 2008, Stark et al., 2008).
DISC1
DISC1 (Disrupted in Schizophrenia 1) was initially identified as a putative susceptibility
gene through analysis of a Scottish pedigree with a (1; 11) (q42.1; q14.3) translocation that
resulted in the disruption of the DISC1 gene (Millar et al., 2000). Family members carrying
the deletion were affected with SZ, depression, and BD (Ishizuka et al., 2006). Additional
independent linkage and association studies in diverse populations have confirmed DISC1 as
a susceptibility gene for SZ (Palo et al., 2007). Several mouse models have been generated
that disrupt DISC1 to evaluate its role in SZ including a truncated DISC1 (DISC1tr)
mimicking the break in the Scottish pedigree, a missense DISC1 (DISC1L100P), and a
dominant negative DICS1 (DN-DISC1) driven by the CaMKII promoter(Clapcote et al.,
2007, Hikida et al., 2007, Shen et al., 2008).
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The DISC1tr mice exhibit several SZ hallmarks including increased lateral ventricles,
decreased cerebral cortex volume, and decreased parvalbumin (PV) expression in the medial
prefrontal cortex (mPFC) (Shen et al., 2008). Additionally, these mice exhibit decreased LI,
and increased immobility in forced swim test (Shen et al., 2008). This model shows promise
as it mimics a break point found in human patients, and possesses some SZ-like pathology.
The DISC1L100P mice also exhibit neuro-anatomical changes seen in schizophrenia patients,
and exhibit behaviors that may be relevant to SZ including decreased PPI, decreased LI,
increased activity in the open field, and decreased performance in the T-maze (Clapcote et
al., 2007). Importantly, treatment with antipsychotics such as haloperidol and clozapine
correct the deficits in PPI, LI, and reduce mobility in these mice (Clapcote et al., 2007).
While this model is a promising model of SZ it does not reflect a mutation found in human
patients.
The DN-DICS1 showed increased volume of the left lateral ventricle, and has decreased
immunoreactivity of PV positive inhibitory neurons (Hikida et al., 2007). These mice
exhibited hyperactivity in the open field, increased immobility in the forced swim test, and a
small deficit in PPI at 74 decibels only (Hikida et al., 2007). This mouse did not show any
difference in Y-maze, Morris water maze, or social paradigms (Hikida et al., 2007). Overall,
DISC1 transgenic mouse models show promise as models of SZ.
Other SZ models
Deficits in glutamatergic transmission through the NMDAR have been implicated in the
expression of SZ (Olney et al., 1999). This hypothesis emerged after the discovery that
phencyclidine (PCP), which primarily acts through blockade of the NMDAR, led to a SZ-
like psychosis and the exacerbation of symptoms in SZ patients (Lodge and Anis, 1982,
Luby et al., 1959). Later studies showed that the use of NMDAR antagonist such as MK-801
also induced psychosis that could be reversed by the administration of antipsychotics such as
clozapine (Olney et al., 1999). Additional studies using brain imaging, postmortem staining,
and genetic manipulation have further implicated NMDAR hypofunction in SZ (Kehrer et
al., 2008). One model which reduces expression of the NR1 subunit of the NMDAR
(NR1hypo) generated by Mohn et al. shows increased sensitivity to PCP, increased open field
activity, decreased social investigation in the resident intruder test , and decreased PPI that is
reversed by treatment with antipsychotics (Duncan et al., 2006b, Duncan et al., 2006a, Mohn
et al., 1999, Moy et al., 2006).
Recently, generation of a transgenic mouse model selectively deleting NR1 expression in
PV positive neurons of the forebrain show increased activity in the open field, increased
anxiety in the elevated plus maze, decreased PPI, mild anhedonia in the saccharine-
preference test after social isolation, and impaired nesting behavior (Belforte et al., 2010).
Thus the glutamate hypothesis and the role of the NMDAR in SZ is a promising model for
studying SZ.
Many other transgenic mouse models are currently being characterized as models of SZ
including ErbB4, Adenosine Kinase, Complexin 1, mGluR1, and many more. Additionally,
there are many developmental, drug induced, and lesion preparation models that are outside
the scope of this review. For a comprehensive list of mouse models of schizophrenia go to
http://www.schizophreniaforum.org/res/models/Animal_Models_04_09.pdf.
VI. Future Directions
Transgenic animal models are important tools for studying the molecular, cellular, and
circuitry mechanisms of childhood onset psychiatric disorders. In this review we attempted
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to introduce current transgenic models for ADHD, ASD, Mood Disorders, OCSD, and SZ.
Here we will focus on general future directions for designing useful animal models. We will
highlight the newest technologies available and discuss the advantage and limitations of
these technologies.
Modeling Human Variations/Mutations in Mice
Many of the models presented in this review aim to delete or overexpress genes implicated
in childhood onset psychiatric disorders. These mouse models have been very helpful in
confirming the involvement of these genes in psychiatric disorders, and in some cases have
provided insight into specific brain regions that may be involved in the expression of some
of the disorders features. However, in many human patients, psychiatric disorders do not
arise from a complete deletion or duplication of a gene. Human genetic studies have
identified many rare variations or mutations within genes of interest which are thought to
contribute to the expression of psychiatric disorders (Hudziak and Faraone, 2010). Some
labs have begun to generate mice that mimic break points or variations observed in human
patients, and these models show promise as models for their respective disorders (Chadman
et al., 2008, Shen et al., 2008, Tabuchi et al., 2007, Veenstra-Vanderweele et al., 2009).
Thus, generating mouse models that replace the endogenous gene with a variation or
mutation identified in human populations will reflect conditions observed in human patients,
and may allow for better elucidation of the etiology of these childhood onset psychiatric
disorders.
New Tools for the Study of Brain Function
Cre-Lox System—The concept of using cre-lox systems to target specific brain regions or
neuronal populations is not new, however this technique is continually advancing. Cre can
be expressed either globally or conditionally in subpopulations of cells/organs (Gaveriaux-
Ruff and Kieffer, 2007, Wolf and Woodside, 2005). Currently, traditional and inducible cre
lines are available (Heldt and Ressler, 2009, Utomo et al., 1999). Traditional cre lines
express cre in the temporal and spatial pattern of the selected promoter. Inducible cre lines
express cre in the specific pattern after administration of a drug such as tamoxefin (Cre-ER)
(Feil et al., 1997). As the temporal and spatial expression patterns of more genes are
characterized, the available cre-lines will greatly increase. Many groups, along with gene
expression nervous system atlas (GENSAT) project and Allen Brain Institute, have
characterized hundreds of genes and their expression patterns to date. The advantage of this
method over a global knockout/over-expression is that using specific promoters allow for
targeting and manipulation of specific brain regions or sub-populations of neurons.
Importantly, this method can be beneficial when global effects result in lethality or
developmental problems not associated with the disorder of interest. One limitation of this
approach is that genes are generally expressed in many brain areas. Thus, while scientists
can target selected sub-populations of neurons using different promoters, it is difficult to
target specific brain regions without expression in other areas using transgenic cre mouse
lines. Viral injection of cre driven by a specific promoter circumvents this problem.
Additionally, the expression pattern has not been characterized for all genes, therefore a
transgenic cre mouse line may not currently exist that targets the specific population of
interest. As more and more genes are characterized, this limitation will be marginalized.
Another issue to be mindful of in using this technique is that often cre-lines do not affect
100% of the target population, and sometimes ectopic expression of cre occurs. Careful
characterization of new cre-lines using reporter lines that express fluorescence in the
presence of cre will be required to verify the expression pattern (Wang, 2009).
One advancement to the cre-lox system is the inverted and double floxed with LoxP and
mutant LoxP (mLoxP) FLEX switch (Atasoy et al., 2008, Nyabi et al., 2009, Schnutgen et
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al., 2003). This system allows for flanking of a genomic region of interest, where in the
presence of Cre a region of DNA is inverted to change the expression pattern of the gene of
interest. For example, exons can be inverted leading to the generation of a knockout mouse
in the absence of cre. In the presence of cre the exons will be inverted again restoring
protein expression. Additionally, this method can be used to flank exons with loxP/mloxP
sites where in the absence of cre there is normal gene expression and in the presence of cre
the exons are inverted resulting in a loss of gene expression. Thus, the FLEX method can be
used to generate a cre-induced gene rescue using the original gene locus as well as a
traditional cre-induced knockout. The FLEX method maintains the advantages of using cre-
lines including temporal and spatial control over gene replacement/knockout expression.
Optogenetics—Another new method available is optogenetics, channelrhodopsin and
halorhodopsin (Arenkiel et al., 2007, Zhang et al., 2008, Zhao et al., 2008).
Channelrhodopsin is a non-selective cation channel that is activated by blue light (473nm),
which leads to neuronal activation. Halorhodopsin is a chloride pump that is activated by
yellow light (580nm) and leads to neuronal silencing. These channels can be expressed
using any of the currently available techniques including cre-lox, viral delivery, or knock-in.
The advantage of this method is the ability to stimulate or silence specific neurons rapidly
and effectively both in vivo and in vitro (Airan et al., 2009, Cardin et al., 2009, Cardin et al.,
2010, Zhang et al., 2010). Importantly, in vivo recording of neuronal activation by field
local potentials (FLPs) or specific regulation of single neurons by whole cell recordings is a
rapidly advancing technique used to study psychiatric disorders in animal models (Stuber,
2010, Zhang et al., 2010). These recording techniques allow for the study of neuronal
signaling in an intact system, and can be used in both anesthetized and awake behaving
animals (Adamantidis et al., 2010, Cardin et al., 2009). Optogenetics facilitates the
effectiveness of these recording techniques by allowing for rapid and precise stimulation/
silencing of specific neurons or brain regions to generate specific firing patterns (Cardin et
al., 2009, Cardin et al., 2010). The greatest limitation of this technique is that light is
required to activate the channels, therefore direct access to the brain region of interest is
necessary. Currently, in vivo experiments require surgery to place cannulas and attachment
of a fiberoptic cable to deliver the light pulses. Thus, damage to other brain regions is a
confounding issue. Additionally, the ability to perform behavioral studies is severely limited
due to the fiberoptic cables attached to the head of the animal.
Chemicogenetics—The final method we will introduce is chemicogenetics (Conklin et
al., 2008, Dong et al., 2010, Nichols and Roth, 2009, Pei et al., 2010). One example is the
“designer receptor exclusively activated by a designer drug” (DREADD) strategy.
DREADD receptors are mutated muscarinic acetylcholine (mAch) receptors that no longer
respond to Ach and are selectively activated by clozapine-N-oxide (CNO) (Alexander et al.,
2009, Armbruster et al., 2007). M4 receptors are Gi coupled receptors that leads to neuronal
silencing by inhibiting adenylate cyclase (AC) levels and prolonging potassium channel,
non-specific cation channel and transient receptor channel opening (Eglen, 2006). The M3
receptor is a Gq coupled receptors that leads to neuronal activation by mobilizing
phosphoinositides and decreasing intracellular calcium levels (Eglen, 2006). Thus, M4-
DREADDs lead to neuronal silencing while the M3-DREADDs result in neuronal
activation. DREADD receptors, like channelrhodopsin and halorhodopsin can be introduced
using any of the currently available techniques. Importantly, this method can be used in vivo
as CNO can pass through the blood brain barrier (Alexander et al., 2009). Advantages to this
method are that behavioral studies are not limited as there is no external equipment attached
to the mouse. Additionally, CNO is completely inert in cells not expressing DREADD
receptors, therefore complications due to drug related side effects are not an issue. Thus, this
technique shows great promise for behavioral studies.
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One limitation for this method is that delivery of CNO is on a much slower time scale than
the rapid control of optogenetics so studies of direct stimulation/silencing effects on
signaling are limited in this model. A second limitation is that the method has not been
characterized in all cell types and may not work in all systems due to differential expression
of signaling pathways required for DREADD receptor-mediated neuronal activation/
silencing.
VII. Conclusions
In conclusion, studies using animal models have greatly increased our understanding of
childhood onset psychiatric disorders. As discussed earlier, it is impossible to model an
entire psychiatric disorder in a single mouse model, however these models can be very
useful in characterizing a specific behavior or physical feature of a disorder. Additionally,
many characteristics of childhood onset psychiatric disorders are shared between disorders.
For example, repetitive behaviors are seen in both OCD and ASD. Therefore, when
considering the validity of a transgenic mouse model, one should evaluate the validity for
select behaviors or a particular feature rather than the validity of a mouse for a particular
psychiatric disorder. Thus far, animal models have played important roles in validating
candidate genes related to specific disorders, identifying and confirming the involvement of
signaling pathways in specific behaviors/disorders, and in identifying potential targets for
development of new therapeutics. One future goal is to compare different models that share
a common behavior or characteristic to identify common neuronal circuitry defects involved
in the expression of that behavior. The newest technologies discussed in this review can then
be used to test and confirm the involvement of a particular circuitry network or population
of neurons allowing for a deeper understanding of the underlying causes of psychiatric
disorders.
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Table 1
Table of common behavior tests used to characterize animal models of childhood onset psychiatric disorders.
Behavior Test Description
Anxiety/Fear:
Active/Passive Avoidance Measures the avoidance of an area where a foot shock was given. Passive avoidance required the
mouse to not enter the area where the foot shock was presented. Active avoidance requires the
mouse to exit the area where the foot shock was presented upon a cue.
Contextual Fear Conditioning Measures the amount of freezing when placed in an environment where a previous negative
stimulus (foot shock) was given
Elevated Plus Maze Measures time spent in the open arm versus protected arm of a cross-shaped arena
Elevated Zero Maze Measures time spent in the open area versus protected area of a circular arena
Light Dark Emergence Measures latency to emerge from the dark chamber to the light chamber. Also measure total time
spent in light and dark chambers, and activity levels in these chambers
Open Field Measures time spent in the center of the open field arena versus the perimeter or corners of the
arena
Reward/Aversion Measures the latency to obtain a reward in the presence of an aversive stimulus (ex. predator urine,
brightly lit novel arena)
Compulsive Behavior:
Marble Burying Measures the number of marbles buried as a result of compulsive digging or shifting in bedding
Non-nutritive Chewing Measures amount of chewing of non-nutritive clay or substances
Repetitive Grooming Measures number of grooming sessions and total time spent grooming in a 24 hour period. Also
measures time spent grooming relative to other adaptive behaviors (eating, sleeping)
Depression:
Learned Helplessness Measures latency to escape a foot shock after repetitive training with foot shock in an inescapable
chamber
Porsolt Forced Swim Measures the time spent in vigorous swimming relative to the time spent floating in a tall cylinder
filled with water
Tail Suspension Measures the time spent struggling relative to the time spent immobile when suspended by the tail
Learning and Memory:
Barnes Maze Measures the ability to learn the location of an escape hole in a circular maze with 18 evenly
spaced holes using spatial environmental cues
Morris Water Maze Measures the ability to learn the location of a hidden platform using extra-maze spatial
environmental cues
Radial Arm Measures the number of entries into one of eight arms that are baited with food or water using
spatial environmental cues; may tap into cognitive preservation
T Maze/Y-Maze Measures the correct initial entry into an alternating arm of the maze bated with food or water using
spatial environmental cues; may tap into cognitive preservation
Social Paradigms:
Nest Building Evaluates size and organization of nest building; may also assess procedural cognitive function
Pairing in Novel Environment Measures amount of social approach of two mice paired in a novel environment
Resident Intruder Measures amount of social approach when an intruder mouse is introduced into the home cage of
the test mouse following social isolation
Social Approach-Partitioned Measures amount of time spent near the partition dividing the test mouse from either a stranger or
known mouse.
Social Approach- Three Chamber Measures amount of time spent in an empty chamber versus a chamber containing a stranger
mouse. Second trial measures the time spent in the chamber with a known mouse versus a stranger
mouse versus an empty chamber
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Behavior Test Description
Social Recognition Measures the amount of social interaction between the test mouse and a second mouse on the first
and subsequent exposures
Ultrasonic Vocalization-Adults Measures the number and duration of ultrasonic vocalizations of male mice exposed to female mice
in estrous OR male mice during a resident intruder test
Ultrasonic Vocalization- Neonates Measures the number and duration of ultrasonic vocalizations of pups during brief isolation from
the dam and/or littermates
Other:
Delayed Reinforcement Measures the ability to wait for a preferred reinforcer (ex. water) over the immediately available
less-preferred reinforce (ex. quinine). The time for the preferred reinforcer increases with each trial.
Reaction-Time Task Measures the number of nose poke entries to receive a reward during a cued time period.
Home Cage Activity Measures the amount of total, horizontal, and vertical activity in a home cage environment to test
for habituation
Latent Inhibition Measures the impaired performance during an active avoidance task when test training includes
exposure to the cued stimulus but without any reinforcement contingencies
Open Field Activity Measures the amount of total, horizontal, and vertical activity in a novel environment; other
activities including stereotypic or repetitive patterns of movement can also be assessed
Pre-pulse Inhibition/Sensory Motor
Gating
Measures the inhibition of a reflexive acoustic startle response to be inhibited when weaker stimuli
are presented prior to the startle stimulus
Running Wheels Measures the amount and duration of activity in a 24 hour period. Manipulation of light and dark
cycles can allow for measuring circadian rhythm based on activity patterns over several months
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